RecruitingPhase 2NCT06904313

Ultralow Dose PET Imaging for PSMA Expression

Evaluation of Ultralow Dose PET Imaging for Detecting PSMA Expression


Sponsor

Akiva Mintz

Enrollment

200 participants

Start Date

May 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours


Eligibility

Min Age: 18 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a very low-dose PET scan can accurately detect a protein called PSMA on cancer cells — the same information currently requiring standard higher-dose scans — reducing patients' radiation exposure during imaging. **You may be eligible if...** - You are 18 or older - You are able to give informed consent and follow study procedures - Women of childbearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test **You may NOT be eligible if...** - You have already received the maximum allowed radiation from research scans (50 mSv per year) - You have enrolled in this specific study more than four times previously - You have severe claustrophobia, chronic pain, or a physical condition that prevents you from completing a PET scan - You are currently receiving PSMA-targeted radiation therapy (e.g., lutetium-177) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPiflufolastat F18

Participants will be injected with Piflufolastat F18 and imaged for up to 3 hours on a PET scanner


Locations(1)

Nuclear Imaging Institute

Englewood, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06904313


Related Trials